Novo Nordisk Using Priority Review Voucher To Propel Oral Semaglutide To Market

 
• By Sten Stovall
Track
Novo Nordisk Aims to cut FDA review time to six months for its oral GLP-1. • Source: Shutterstock

More from New Products

More from Scrip